| Jeannie Long, LCSW | |
|
5808 W 110th St, Overland Park, KS 66211-2504 | |
| (913) 696-8000 | |
| Not Available |
| Full Name | Jeannie Long |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 5808 W 110th St, Overland Park, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073890786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 1309 (Kansas) | Primary |
| 1041C0700X | Social Worker - Clinical | 2009025845 (Missouri) | Secondary |
| Entity Name | The Childrens Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851437719 PECOS PAC ID: 2466366026 Enrollment ID: O20050721001065 |
News Archive
Research Councils UK (RCUK) welcomed the recommendations made in the NAO's Value for Money study of the project to establish the RCUK Shared Service Centre. We thank the NAO for endorsing, through their recommendations, the approach that the Research Councils are already taking to ensure that the SSC's service matures quickly.
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
A Boston University School of Medicine study shows a mind-body class elective for medical students helps increase their self-compassion and ability to manage thoughts and tasks more effectively.
Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeannie Long, LCSW 2401 Gillham Rd, Provider Enrollment, Kansas City, MO 64108-4619 Ph: (816) 701-5200 | Jeannie Long, LCSW 5808 W 110th St, Overland Park, KS 66211-2504 Ph: (913) 696-8000 |
News Archive
Research Councils UK (RCUK) welcomed the recommendations made in the NAO's Value for Money study of the project to establish the RCUK Shared Service Centre. We thank the NAO for endorsing, through their recommendations, the approach that the Research Councils are already taking to ensure that the SSC's service matures quickly.
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
A Boston University School of Medicine study shows a mind-body class elective for medical students helps increase their self-compassion and ability to manage thoughts and tasks more effectively.
Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
› Verified 9 days ago
Mrs. Elizabeth Minton Christian, LSCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8101 Overland Park Dr, Overland Park, KS 66204 Phone: 913-383-2292 | |
Bailee Greenhaw, LSCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 14623 Grant Ln, Overland Park, KS 66221 Phone: 913-980-5569 | |
Renee Lynn Van Meter, LSCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8000 W 127th St, Overland Park, KS 66213 Phone: 816-508-3273 | |
Ms. Heather Anne Astill, MSW, LSCSW, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6700 W 121st St Ste 102, Overland Park, KS 66209 Phone: 202-681-4747 | |
Ms. Laurie Anne White, LMSW, LMAC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7040 Antioch Rd, Overland Park, KS 66204 Phone: 913-952-2929 | |
Ms. Judy May Funk, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10042 Knox Dr, Overland Park, KS 66212 Phone: 913-894-2734 Fax: 913-894-2734 | |
Allison Michelle Kidd, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8000 W 127th St, Overland Park, KS 66213 Phone: 913-951-4300 |